Home/Filings/4/0001127602-23-029839
4//SEC Filing

Thackray Helen M. 4

Accession 0001127602-23-029839

CIK 0000882796other

Filed

Dec 17, 7:00 PM ET

Accepted

Dec 18, 4:47 PM ET

Size

8.7 KB

Accession

0001127602-23-029839

Insider Transaction Report

Form 4
Period: 2023-12-14
Thackray Helen M.
Chief R&D Officer
Transactions
  • Award

    Common Stock

    2023-12-14+51,000258,275 total
  • Award

    Emp. Stock Option (Right to Buy)

    2023-12-14+238,000238,000 total
    Exercise: $6.43From: 2024-12-14Exp: 2033-12-14Common Stock (238,000 underlying)
  • Tax Payment

    Common Stock

    2023-12-14$6.43/sh3,031$19,489255,244 total
Footnotes (3)
  • [F1]Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
  • [F2]Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person.
  • [F3]Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Issuer

BIOCRYST PHARMACEUTICALS INC

CIK 0000882796

Entity typeother

Related Parties

1
  • filerCIK 0001589725

Filing Metadata

Form type
4
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 4:47 PM ET
Size
8.7 KB